Search

everythinglearnresearchcommunity

for

Search:↓

A female user starting Spironolactone treatment for thinning hair, and others sharing their experiences with Minoxidil and oral/sublingual Minoxidil as treatments.

User had success with dutasteride for hair loss after finasteride didn't work. Some experienced increased cholesterol and debated its relation to DHT.

Jordan-Iliad has been using a combination of finasteride, minoxidil, stemoxydine, microneedling, saw palmetto, peppermint and jojoba oils, ketoconazole shampoo, and Purador shampoo/conditioner for 3 months to treat their hair loss with stunning results. They have also recently started taking oral minoxidil 1.25mg/day in hopes of achieving even better results over the next 3 months.

Hair loss and scalp issues, with people discussing possible treatments such as Nizoral shampoo, Minoxidil, neem oil, and finasteride.

N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.

A 26-year-old man from France started experiencing hair loss in September 2020 and began using finasteride in June 2021, reporting some improvement after three months without side effects. He plans to continue finasteride for a year before considering additional treatments like minoxidil or dermarolling.

Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.

Low-dose Dutasteride, used 2-3 times a week, is as effective as daily Finasteride for hair loss with fewer side effects. Users report increased libido and better results with Dutasteride compared to Finasteride.

Regret over not starting hair loss treatments like finasteride and minoxidil earlier, leading to significant hair loss. Users discuss coping strategies, including buzzing hair, staying on medications, and considering future treatments.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

Hair loss treatments, such as Dutasteride, Minoxidil, and Finasteride. Advice is given to give the medications time to work and to consider a Hair Transplant in order to fill any gaps caused by continuing hair loss.

A 14 year old who is experiencing hair loss and has not received any help from the doctor, with advice being given to try different doctors, get tested for underlying conditions and intolerances, buzz it short as an option and treatments that could slow down or reverse the hair loss such as minoxidil, finasteride, RU58841 and addressing the cause of the hair loss.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses the potential of new hair loss treatments, with a focus on pyrilutamide, gt20029, and topical alfatradiol, and the possibility of improving their effectiveness through methods like increased concentration and microneedling. Dutasteride is also mentioned as a stronger option.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.